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Abstract
Background
Ribavirin blood levels vary considerably between patients with standard weight-based dos-
ing. Their impact on sustained virological response (SVR) with pegylated interferon and
ribavirin is controversial, but has mostly been studied before the IL28b gene polymorphism
as a possible confounder was discovered.
Methods
The impact of serum ribavirin trough levels at week 4, at the end of treatment and of mean
levels across the entire antiviral treatment with pegylated interferon and ribavirin on relapse,
SVR rates and anemia was retrospectively studied by univariate and multivariable logistic
regression analyses in 214 patients with HCV genotype 1–4 infection, including 88 patients
with available IL28b genotyping.
Results
Mean ribavirin levels varied between 0.68–5.65 mg/l and significantly differed between
patients with or without SVR. By multivariable regression including age, sex, HCV viral
load, HCV genotype, liver fibrosis stage, prior treatments, immunosuppression and
IL28b genotype, ribavirin levels consistently displayed significant influence on SVR and
relapse without indication for a specific importance of higher concentrations early or late
in the treatment course. Although hemoglobin decline was on average more pronounced
in patients with higher ribavirin levels, hemoglobin remained relatively stable in a signifi-
cant proportion of these, indicating that ribavirin levels alone are insufficient to predict
anemia.
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Conclusion
While data are scarce to draw conclusions applicable for modern DAA therapies, these
results support ribavirin treatment based on serum levels instead of purely weight-based
dosing in combination with pegylated interferon.
Introduction
Pegylated interferon and ribavirin have been the standard treatment for Hepatitis C virus
(HCV) infection for more than a decade and are still in use in many developing countries.
Although new directly acting antiviral drugs (DAAs) inhibiting the viral protease, polymerase
and the non-structural protein 5a have enormously improved efficacy and tolerability
approaching 100% cure rates in patients with favorable characteristics predicting treatment
response [1], patients with liver cirrhosis or HCV genotype 3 infection remain difficult to treat
populations where ribavirin is still a key drug to improve SVR rates [2–6]. Thus, despite ane-
mia as a frequent side effect, ribavirin continues to be part of modern antiviral treatment
regimens.
In combination with pegylated interferon, guidelines recommended weight-based ribavirin
dosing between 1000–1200 mg/d for HCV genotypes 1 and 4, and a fixed dose of 800 mg/d for
treatment of HCV genotypes 2 and 3 [5, 7]. However, ribavirin plasma levels vary considerably
between patients even with weight-based dosing [8]. Since ribavirin has a narrow therapeutic
range with anemia as a frequent side effect, monitoring of plasma levels might be useful to opti-
mize treatment outcomes and avoid unnecessary toxicity. Multiple studies described a benefit
of higher ribavirin doses on sustained virological response (SVR) rates, but are challenged by
almost equal numbers of studies reporting contradictory results [9]. Interpretation is limited
(critically reviewed in [9]) by differences in patient populations and study end points, often
small sample sizes, and the fact that only some of the few, mostly retrospective studies that
measured plasma or serum ribavirin levels consistently obtained these as trough levels as neces-
sary at least for the investigation of the first 4–8 weeks of treatment until steady state levels are
established [10]. Last, most publications came out before the IL28b gene polymorphism was
discovered as one of the strongest factors influencing response rates with pegylated interferon
and ribavirin therapy, thus representing a possible confounder for all past analyses regarding
the effect of ribavirin. Currently, only five studies considering the IL28b gene polymorphism—
three of them on HIV/HCV coinfected patients—have been published. While the two publica-
tions on HCV mono-infected patients favored higher ribavirin levels, conflicting results were
observed in the HIV/HCV co-infected cohorts. However, each study focused on special patient
subgroups, ribavirin dosing strategies or sample time points [11–15]. Thus, it is still unclear
whether ribavirin concentrations might be relevant and could warrant therapeutic drug moni-
toring in anti-HCV treatment.
We therefore conducted a retrospective study on the influence of ribavirin serum concentra-
tions on SVR and relapse rates considering IL28b genotypes, as well as on anemia in patients
treated for HCV genotype 1–4 infection with pegylated interferon and ribavirin at the Univer-
sity Hospital Zürich between 2005 and 2013.
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Patients and Methods
Study Population
Adult Caucasian patients who had received anti HCV treatment between July 2005 and June
2013 were retrospectively screened for the study. Inclusion criteria were infection with HCV
genotypes 1–4, treatment with pegylated interferon and ribavirin with known outcome, and
availability of serum ribavirin trough level measurements. Exclusion criteria were non-
standard treatment durations or interferon dose reductions preventing assessment of the treat-
ment response. The only HIV positive patient in the cohort achieved SVR, so that HIV infec-
tion appeared no relevant confounder in this case and the patient was kept in the study. The
study was conducted according to the Declaration of Helsinki and current guidelines on Good
Clinical Practice and was approved by the Cantonal Ethics Committee Zürich, that waived the
need for individual patient consent acknowledging the non-interventional and retrospective
character of the study. Patient information was anonymized and de-identified prior to the sta-
tistical analysis.
Treatment Regimens and Assessment of Response
Patients were treated with pegylated interferon alpha 2a or 2b and ribavirin at weight-based
dosages and for treatment durations according to standard guidelines [5, 7]. Anemia was man-
aged with ribavirin dose reduction, erythropoietin or transfusions as necessary, and in some
cases the ribavirin dose was increased in patients with low plasma ribavirin through levels at
the discretion of the treating physician. Treatment was considered sufficient if patients had
completed at least 90% of the recommended treatment duration without interferon dose reduc-
tion. In patients with pre-treatment viral load< 800.000 IU/ml and undetectable HCV RNA at
treatment week 4 (rapid virological response, RVR) treatment could be shortened from 48 to
24 weeks for HCV genotypes 1 and 4, or from 24 to 16 weeks for HCV genotypes 2 and 3.
Patients who did not achieve a two log reduction in their viral load at treatment week 12 (early
virological response, EVR) were considered non-responders and treatment was discontinued.
An undetectable HCV RNA 24 weeks after the end of treatment was considered a sustained
virological response (SVR).
Non-standard treatment durations. An extension of the treatment duration by 24 weeks
was allowed in patients with negative predictors including cirrhosis, failed prior treatment with
pegylated interferon and ribavirin, or immunosuppression after transplantation [5, 7], but was
considered as an influencing factor in the multivariate analysis to avoid confounding effects.
Significantly (>10%) shorter than recommended treatment durations were observed because
of early discontinuations in case of intolerable side effects, receipt of a transplant organ, newly
diagnosed cancer, infections, death or loss to follow up. Patients who nevertheless achieved
SVR were counted as responders. All other patients with non-standard treatment durations
that did not allow classification of their treatment response were excluded from the analysis.
Measurements and Laboratory Tests
Patients were followed using a standardized treatment schedule with regular visits and stan-
dardized lab sheets including ribavirin trough level measurement in weeks 4, 12, 24 and 48,
and at additional time points as felt necessary by the treating physician. Serum ribavirin trough
levels were measured using high-performance liquid chromatography tandem mass spectrom-
etry using a validated and accredited method by the hospital’s central clinical chemistry lab,
and mean values from all available time points were calculated using the linear trapezoid rule.
If the ribavirin dosage was changed during the treatment course, patients were only included in
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the study if at least one subsequent ribavirin measurement reflecting the change was available.
Liver fibrosis was assessed according to the Metavir score [16] either from pre-treatment liver
biopsies, or from fibroscan measurements with conversion to Metavir scores with cutoff levels
according to Castera et al. [17]. HCV RNA levels were determined using Cobas Ampliprep
Taqman HCV quantitative tests (Roche Diagnostics, Switzerland). IL28b genotyping for SNP
rs12979860 was performed using the LightMix Kit IL28b (Tib Molbiol, Berlin, Germany) on a
Roche LightCycler (Roche Diagnostics, Switzerland).
Statistical Analysis
Continuous variables were compared by Mann-Whitney-U test and categorical variables by
chi-square test or Fisher’s exact test as appropriate using SPSS software version 23 (IBM Corp.,
Armonk, NY). Variables with significant results in the univariate analysis and ribavirin levels
were entered into a logistic regression analysis to evaluate independent factors influencing SVR
in the entire study population, or in subgroups of patients based on HCV genotypes and avail-
ability of IL28b genotyping. P-values< 5% were considered significant.
Results
Study Population
To analyze the impact of ribavirin serum levels and IL28b genotypes together with other
known influencing factors on anti-HCV treatment response rates, a total of 276 patients were
retrospectively screened. Of these, 214 patients had sufficient ribavirin measurements and
information on treatment outcome, as well as HCV genotype, liver fibrosis stage, baseline
HCV RNA levels, treatment duration, prior treatments, sex, age and immunosuppression as
previously described factors influencing treatment outcome [5, 7] available and could be
included applying the inclusion and exclusion criteria. IL28b genotyping was available for 88
patients (54 for genotypes 1 and 4, and 34 for genotypes 2 and 3). SVR was achieved by 43/77
(56%) patients with genotype 1, 22/26 (85%) patients with genotype 2, 59/82 (72%) patients
with genotype 3 and 15/29 (52%) patients with genotype 4. Patient characteristics and SVR
rates are displayed in Tables 1–3.
Variability of Serum Ribavirin Levels
Serum ribavirin concentrations were measured a median of 3 times (mean 3.33, range 1–7)
during treatment, with intrapatient mean values calculated over the entire treatment duration
ranging between 0.68 and 5.65 mg/l. The median intrapatient variability was 16% (IQR 42%,
range 0–49%) in patients with constant ribavirin dosage throughout the treatment course and
at least two available measurements, and slightly higher (19%, IQR 55%, range 3–86%) in
patients with dose adjustments. Comparing mean ribavirin serum levels between patients with
different HCV genotypes and treatment responses, these varied between 1.9 mg/l and 3.0 mg/l
(Tables 1–3). As demonstrated in previous reports [8, 11–13] these values illustrate the consid-
erable inter-individual variability in ribavirin plasma levels with standard ribavirin dosing.
Factors Influencing Sustained Virological Response
Multiple studies have investigated factors that influence the outcome of antiviral treatment
with pegylated interferon and ribavirin [5, 7]. By univariate analysis including the full dataset,
consistent with previous reports Metavir fibrosis scores, HCV RNA levels, age, sex, HCV geno-
type and prior unsuccessful treatment showed significant differences between patients with or
without SVR, whereas—possibly because of the relatively low numbers of patients with these
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characteristics in our cohort—immunosuppression, extended treatment duration and IL28b
CC versus non-CC genotype did not reach significance. Regarding the impact of ribavirin,
mean levels over the entire treatment duration and ribavirin levels at week 4 and at the end of
treatment were significantly different between patients achieving SVR and those who could not
be cured (Table 1). A separate analysis grouping patients with genotypes 1/4 or 2/3 yielded sim-
ilar results, with the only exception that mean ribavirin levels over the entire treatment dura-
tion did not reach significance in the genotype 1/4 subgroup (Tables 2 and 3).
Variables with significant results by univariate analysis were entered into a logistic regres-
sion model. Here, liver fibrosis, HCV viral load, ribavirin levels at all three analyzed time
points, HCV genotype and prior unsuccessful treatment were still associated with SVR,
whereas age and sex failed the level of significance. When the analysis was restricted to patients
Table 1. Patient characteristics and SVR rates.
All HCV Genotypes
N (All) SVR non-SVR p
N 214 139 75
Age, mean (range) 214 44.9 (20–72) 50.5 (25–69) 0.001
Sex 0.025
male, n (% SVR) 144 86 (60%) 58 (40%)
female, n (% SVR) 70 53 (76%) 17 (24%)
Log10 HCV-RNA, mean (range) 214 5.7 (2.7–7.4) 6.2 (4.7–7.3) 0.002
Metavir Fibrosis Score, n 0.002
F0-1, n (% SVR) 80 60 (75%) 20 (25%)
F2, n (% SVR) 62 39 (63%) 23 (37%)
F3, n (% SVR) 27 13 (48%) 14 (52%)
F4, n (% SVR) 29 11 (38%) 18 (62%)
missing 16 16 (100%) 0 (0%)
Treatment status, n (%) < 0.001
Treatment naive 170 125 (73.5%) 45 (26.5%)
Treatment experienced 44 14 (32%) 30 (68%)
Standard Interferon ± Ribavirin 26 6 (23%) 20 (77%)
Pegylated Interferon + Ribavirin 18 8 (44%) 10 (56%)
Immunosuppression, n (%) 0.58
Yes 25 15 (60%) 10 (40%)
No 189 124 (66%) 65 (34%)
Extended treatment duration, n (%) 0.84
Yes 27 18 (67%) 9 (33%)
No 187 121 (65%) 66 (35%)
IL28b rs12979860 0.85
CC, n (%) 28 16 (57%) 12 (43%)
CT/TT, n (%) 60 33 (55%) 27 (45%)
missing, n 126
Ribavirin serum level (mg/l), mean (range)
Week 4 171 2.4 (0.6–6.7) 2.0 (0.2–5.3) 0.015
End of treatment 113 2.7 (0.0–6.2) 2.3 (0.5–4.6) 0.024
Mean, full treatment duration 214 2.7 (0.7–5.7) 2.4 (0.9–5.3) 0.045
Patient characteristics and cofactors analyzed regarding treatment outcome with rates of sustained virological response (SVR) for all patients. P-values of
univariate analyses are indicated. (Mann-Whitney-U Test, Chi-Squared Test or Fisher's exact Test were used as appropriate.)
doi:10.1371/journal.pone.0158512.t001
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with available IL28b genotyping to include this variable in the model, mean ribavirin levels
over the full treatment period or at week 4, prior unsuccessful treatment and baseline HCV
viral load remained significant factors influencing SVR rates (Table 4).
Taken together, both by univariate and by multivariate analysis including important
described covariables, ribavirin serum levels turned out to be one of the strongest factors signif-
icantly influencing the outcome of anti-HCV treatment with pegylated interferon and ribavirin
in our study.
Factors Influencing Relapse
Some previous studies have focused on the role of ribavirin concentrations at specific time
points such as week four or the end of treatment, with a recent publication indicating that
Table 2. Patient characteristics and SVR rates for HCV Genotypes 1 and 4.
HCV Genotype 1 and 4
N (All) SVR no SVR p
N 106 58 48
Age, mean (range) 106 45.4 (20–71) 50.1 (25–69) 0.008
Sex 0.35
male, n (% SVR) 77 40 (52%) 37 (48%)
female, n (% SVR) 29 18 (62%) 11 (38%)
Log10 HCV-RNA, mean (range) 106 5.7 (3.0–7.4) 6.2 (4.7–7.2) 0.005
Metavir Fibrosis Score, n 0.001
F0-1, n (% SVR) 43 30 (70%) 13 (30%)
F2, n (% SVR) 35 20 (57%) 15 (43%)
F3, n (% SVR) 17 7 (41%) 10 (59%)
F4, n (% SVR) 10 0 (0%) 10 (100%)
missing 1 1 (100%) 0 (0%)
Treatment status, n (%) 0.006
Treatment naive 72 46 (64%) 26 (36%)
Treatment experienced 34 12 (35%) 22 (65%)
Standard Interferon ± Ribavirin 21 4 (19%) 17 (81%)
Pegylated Interferon + Ribavirin 13 8 (61.5%) 5 (38.5%)
Immunosuppression, n (%) 0.66
Yes 18 9 (50%) 9 (50%)
No 88 49 (56%) 39 (44%)
Extended treatment duration, n (%) 1.00
Yes 8 4 (50%) 4 (50%)
No 98 54 (55%) 44 (45%)
IL28b rs12979860 0.29
CC, n (%) 17 10 (59%) 7 (41%)
CT/TT, n (%) 37 16 (43%) 21 (57%)
missing, n 52
Ribavirin serum level (mg/l), mean (range)
Week 4 77 2.7 (0.7–6.7) 2.3 (0.2–5.3) 0.049
End of treatment 57 3.0 (0.0–6.2) 2.5 (0.5–4.6) 0.047
Mean, full treatment duration 106 3.0 (0.8–5.7) 2.8 (0.9–5.3) 0.13
Patient characteristics and cofactors analyzed regarding treatment outcome with rates of sustained virological response (SVR) separately for patients
infected with HCV genotypes 1 and 4.
doi:10.1371/journal.pone.0158512.t002
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higher end of treatment ribavirin levels might prevent virological relapse [9, 12]. To evaluate
whether high drug concentrations might indeed be of special importance at certain time points
during treatment, we carried out a focused analysis to assess relapse rates in relation to ribavi-
rin levels.
Among 181 patients with end of treatment response, 43 experienced virological relapse– 23/
81 (28%) with genotype 1/4 and 20/100 (20%) with genotype 2/3. By univariate analysis, liver
fibrosis scores (p = 0.015), HCV viral load (p<0.001), age (p = 0.015) and ribavirin levels at the
end of treatment (p = 0.036) differed significantly between relapsers and sustained responders,
and relapses occurred significantly more often in treatment experienced patients (p<0.001),
whereas HCV genotype, extended treatment duration, immunosuppression, IL28b genotype
Table 3. Patient characteristics and SVR rates for HCV Genotypes 2 and 3.
HCV Genotype 2 and 3
N (All) SVR no SVR p
N 108 81 27
Age, mean (range) 108 44.5 (21–72) 49.7 (38–68) 0.05
Sex 0.11
male, n (% SVR) 66 46 (70%) 20 (30%)
female, n (% SVR) 42 35 (83%) 7 (17%)
Log10 HCV-RNA, mean (range) 108 5.8 (2.7–7.2) 6.1 (4.9–7.3) 0.10
Metavir Fibrosis Score, n 0.26
F0-1, n (% SVR) 37 30 (81%) 7 (19%)
F2, n (% SVR) 27 19 (70%) 8 (30%)
F3, n (% SVR) 10 6 (60%) 4 (40%)
F4, n (% SVR) 19 11 (58%) 8 (42%)
missing 15 15 (100%) 0 (0%)
Treatment status, n (%) < 0.001
Treatment naive 98 79 (81%) 19 (19%)
Treatment experienced 10 2 (20%) 8 (80%)
Standard Interferon ± Ribavirin 5 2 (40%) 3 (60%)
Pegylated Interferon + Ribavirin 5 0 (0%) 5 (100%)
Immunosuppression, n (%) 0.68
Yes 7 6 (86%) 1 (14%)
No 101 75 (74%) 26 (26%)
Extended treatment duration, n (%) 1.00
Yes 19 14 (74%) 5 (26%)
No 89 67 (75%) 22 (25%)
IL28b rs12979860 0.43
CC, n (%) 11 6 (55%) 5 (45%)
CT/TT, n (%) 23 17 (74%) 6 (26%)
missing, n 74
Ribavirin serum level (mg/l), mean (range)
Week 4 94 2.1 (0.6–4.5) 1.6 (0.7–3.0) 0.005
End of treatment 56 2.4 (0.6–4.3) 1.8 (0.5–2.7) 0.007
Mean, full treatment duration 108 2.4 (0.7–4.3) 1.9 (1.1–2.9) 0.001
Patient characteristics and cofactors analyzed regarding treatment outcome with rates of sustained virological response (SVR) for patients infected with
HCV genotypes 2 and 3.
doi:10.1371/journal.pone.0158512.t003
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and ribavirin levels at week 4 or mean levels over the entire treatment duration showed no
detectable effect.
Since ROC analyses have identified a plasma threshold around 2 mg/l of ribavirin as an
optimal cutoff level to distinguish responders from non-responders in several studies [12, 18,
19], we also analyzed relapse rates in patients with ribavirin levels above or below 2 mg/l over
the entire treatment period, among which we compared patients where ribavirin levels changed
above or below 2 mg/l at the end of treatment. Of 135 patients with mean ribavirin levels> 2
mg/l, 7 patients had ribavirin levels< 2 mg/l at the end of treatment, all of which achieved
SVR, whereas relapse occurred in 25/128 (19.5%) patients with ribavirin levels stably above 2
mg/l during and by the end of treatment (p = 0.2). In the remaining 46 patients with mean riba-
virin levels below 2 mg/l, relapse rates were again not significantly different between patients
with persistently lower ribavirin levels also by the end of treatment (7/17; 41%) compared to
patients in whom ribavirin levels rose above 2 mg/l at the end of treatment (11/29; 38%;
p = 0.8).
In the multivariate regression model including all factors already analyzed for SVR rates
above, only previous unsuccessful treatment and ribavirin levels at all analyzed time points
(week 4, end of treatment, and mean ribavirin levels over the entire treatment duration)
showed significant influence on relapse rates. The findings remained significant when IL28b
was included in the model, whereby the analysis was restricted to 56, 32 and 67 patients with
available IL28b genotyping for the week 4, end of treatment and entire treatment duration time
points, respectively (data not shown).
Thus, our results support higher drug concentrations in general as a significant factor influ-
encing both SVR and relapse, rather than indicating a special importance of high ribavirin lev-
els at specific time points during the treatment course.
Impact of Ribavirin Serum Levels on Anemia
Previous studies on dual treatment with pegylated interferon and ribavirin found target con-
centrations of 10–15 μM (2.44–3.66 mg/l) ribavirin optimal for balancing high SVR rates with
anemia as the most important ribavirin side effect [20], which is a particular concern still limit-
ing its use also in the era of DAA regimens.
To evaluate whether therapeutic drug monitoring might aid in the prevention of anemia, we
analyzed hemoglobin decline as a function of mean ribavirin serum concentrations in groups
Table 4. Multivariate logistic regression analysis of factors influencing sustained virological response.
Variable All patients (N = 198) Patients with available IL28b genotype (N = 81)
β OR 95% CI p-value β OR 95% CI p-value
Mean ribavirin serum level 1.0 2.7 1.7–4.3 < 0.001 1.2 3.3 1.4–7.8 0.006
Treatment-naive 1.9 6.6 2.9–15.0 < 0.001 2.3 10.4 2.5–42.7 0.001
Fibrosis (Metavir score) -0.4 0.7 0.5–1.0 0.035 -0.5 0.6 0.3–1.3 0.18
HCV genotype 2/3 (vs. 1/4) 1.3 3.5 1.6–7.8 0.002 0.7 1.9 0.5–8.2 0.38
Log10 HCV-RNA -0.4 0.6 0.5–0.9 0.006 -0.4 0.7 0.4–1.1 0.13
Age -0.2 1.0 0.95–1.02 0.33 -0.05 1.0 0.9–1.0 0.20
Female gender 0.2 1.2 0.6–2.6 0.64 0.7 2.0 0.5–7.7 0.30
IL28b CC (vs. CT/TT) - - - 0.1 1.1 0.3–3.8 0.90
Results for the multivariate regression analysis with mean ribavirin serum levels over the full treatment period. Similar results were obtained using ribavirin
levels from treatment week 4. Due to missing liver ﬁbrosis scores or IL28b genotyping, the analysis is restricted to 198 and 81 patients with complete data for
all factors included in the analysis. The regression coefﬁcient β as well as odds ratios with conﬁdence intervals are shown.
doi:10.1371/journal.pone.0158512.t004
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with a hemoglobin decline of more or less than 3 g/dl. Patients on dialysis were excluded
because of the need for anemia management influencing hemoglobin levels independent of
ribavirin treatment in this group. As expected, significantly higher rates of hemoglobin
decline> 3 mg/dl were observed with higher ribavirin concentrations (p = 0.015), illustrating
that optimal drug levels for maximum antiviral efficacy must be balanced with drug toxicity.
Naturally, in none of the patients with hemoglobin decline less than 3 g/dl ribavirin dose reduc-
tion was necessary. Notably, however, less than 3 g/dl hemoglobin decline occurred in 23–27%
of patients with high ribavirin serum levels of> 3 mg/l and up to 5.3 mg/l (Table 5).
Thus, ribavirin serum levels appeared unsuitable for the prediction of its hemolytic effect to
guide ribavirin dosing.
Discussion
In the present multivariate analysis of factors influencing the outcome of anti-HCV treatment
with pegylated interferon and ribavirin, especially also after considering IL28b genotypes we
found a significant influence of ribavirin serum levels both on SVR and relapse rates, remark-
ably with consistently stronger impact compared to other patient characteristics such as older
age or HCV RNA levels. This effect was not limited to early or late time points during treat-
ment, arguing against a special importance of ribavirin only for specific treatment phases.
Although overall anemia was more pronounced in patients with higher ribavirin concentra-
tions, hemoglobin levels remained relatively stable in 23–27% of these, indicating that preemp-
tive strategies avoiding high ribavirin levels might lead to unnecessary under-treatment in a
relevant proportion of patients.
To date, only five studies that also included IL28b genotyping have investigated the role of
ribavirin levels for the outcome of anti HCV treatment. In HCVmono-infected patients, higher
ribavirin levels were associated with lower relapse rates [12] and higher SVR rates [11], whereat
the effect of higher ribavirin concentrations remarkably overcame racial disparities in African
Americans with unfavorable IL28b genotypes, who achieved SVR rates similar to Caucasian
patients [11]. On the other hand, in HIV/HCV co-infected patients only Torres-Cornejo
described a positive influence of higher ribavirin levels on SVR rates in patients with non-
favorable IL28b genotypes [13], whereas two other studies failed to detect a significant influ-
ence on treatment outcome [14, 15], raising the question whether the effect of ribavirin might
be attenuated in the HIV co-infected population that generally achieves lower SVR rates with
pegylated interferon and ribavirin compared to HCV mono-infected patients.
While our results are in line with the two studies on HCV mono-infected patients, as a limi-
tation shared with most publications we cannot exclude possible biases due to the retrospective
nature of our study. In addition we acknowledge that the influence of the IL28b gene polymor-
phism could not be demonstrated in our cohort. A shift in SVR rates up to 40% [21] between
Table 5. Proportion of patients with hemoglobin decline 3 mg/l or > 3 mg/l in groups of increasing
mean serum ribavirin concentrations.
Mean ribavirin concentration Hemoglobin decline
 3 g/dl > 3 g/dl
n (%) n (%)
0–2.00 mg/l 28 (51%) 27 (49%)
2.01–3.00 mg/l 27 (31%) 61 (69%)
3.01–4.00 mg/l 11 (23%) 37 (77%)
> 4.00 mg/l 4 (27%) 11 (73%)
doi:10.1371/journal.pone.0158512.t005
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different IL28b genotypes was described for HCV genotypes 1 and 4, but has shown controver-
sial results in HCV genotypes 2 and 3 in medium-sized datasets [22], perhaps because of a
weaker IL28b impact in these genotypes requiring large cohorts for clarification [23]. There-
fore, with only 106 genotype 1 or 4 and 108 genotype 2 or 3 infected patients, respectively, our
study was likely underpowered for the detection of the influence of IL28b. However, based on
our results it should also be noted that none of the studies focusing on IL28b took ribavirin
concentrations into account, which may explain conflicting results regarding the role of IL28b
in patients with HCV genotype 2 or 3 infection [22, 23].
At present there are only three studies available on the influence of ribavirin concentrations
on SVR rates in the context of DAAs: One analyzed data from trials with interferon, ribavirin
and the protease inhibitors telaprevir or boceprevir, the second studied HCV genotype 1
infected patients that received low dose (600 mg) or weight-based (1000–1200 mg) ribavirin in
combination with sofosbuvir for 24 weeks, and the third combined patients with HCV geno-
type 3 infection treated with sofosbuvir and ribavirin in the Fission, Positron and Fusion trials.
In all three studies higher ribavirin levels were associated with higher SVR rates [24–26]. While
these single DAA regimens have been superseeded by more potent treatment options, ribavirin
is currently still recommended for difficult to treat patients with HCV genotype 1 infection
even when powerful DAA combinations such as sofosbuvir and ledipasvir or ombitasvir, rito-
navir, paritaprevir and dasabuvir are used [1]. The high SVR rates of 97–100% achieved with
these regimens may leave little space for optimization by ribavirin dose adjustment. However,
lower SVR rates are achieved in the treatment of HCV genotype 2 infected patients with sofos-
buvir and ribavirin for 12–16 weeks (60–91%), as well as in the treatment of HCV genotype 3
with pegylated interferon, ribavirin and sofosbuvir for 12 weeks (83–91%), or with ribavirin
and sofosbuvir without interferon for 24 weeks (30–92%), especially if negative predictors such
as cirrhosis or prior unsuccessful treatment are present [1]. Since a clear advantage of higher
ribavirin levels has recently been shown for sofosbuvir and ribavirin treatment for HCV geno-
type 3 [26], it would be interesting to know whether individualized ribavirin dosing might be
useful to optimize treatment response rates in some of these settings.
Hemolytic anemia as the most important ribavirin side effect generally limits dose escala-
tions. Due to the retrospective nature of our study we could not analyze anemia and its man-
agement in detail because different thresholds for ribavirin dose reduction, transfusion or use
of erythropoietin were applied by different physicians, preventing statistical comparisons.
However, even by only focusing on patients with a relatively mild hemoglobin decline< 3 g/dl
that did not require anemia management we could demonstrate that a significant proportion
of these individuals tolerated high ribavirin levels of 3–5.3 mg/l. On the other hand, anemia
has been described to develop with ribavirin concentrations as low as 5–8 μM (1.22–1.95 mg/l)
[20]. Therefore, currently ribavirin levels seem to be of little value to predict anemia, for which
hopefully studies e.g. on polymorphisms in the inosine triphosphatase (ITPA) [27, 28] or the
SLC28A2 [29] genes will enable a more precise view in the future. While ribavirin target con-
centrations of 2.44–3.66 mg/l for dual treatment with pegylated interferon, 2.2–3.6 mg/l for
pegylated interferon, ribavirin and either telaprevir or boceprevir [25], or 4.4–6 pmol/106 red
blood cells for Sofosbuvir plus ribavirin [24] have been published as optimal concentration
ranges to balance the chances for SVR with the rate of anemia< 10 g/dl, we therefore rather
suggest that ribavirin levels of at least 2.5–4 mg/l but without a strict upper limit should be tar-
geted to increase SVR rates, while anemia should be managed by ribavirin dose reduction,
erythropoietin or transfusion on an individual basis when it occurs. The feasibility of higher
dosing combined with monitoring of drug levels to reach target concentrations above 2 mg/l
has been demonstrated in several trials. Different strategies with either calculation of the opti-
mal ribavirin dose based on weight and renal function [30–33], or the use of a pre-treatment
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ribavirin test-dose were applied [34], whereby the proportion of patients that would only
achieve inadequately low ribavirin exposure using standard weight-based dosing may be
reduced considerably. Notably, in a study comparing an intensified regimen with 2000 mg
ribavirin per day for the first four weeks of treatment against normal weight based ribavirin
dosing, the decline in hemoglobin could well be compensated by erythropoietin [14]. Given
that DAA treatment durations are as short as 8–12 weeks, it appears well possible that anemia
may be manageable for this limited time even with higher ribavirin dosing.
Taken together, we here demonstrate a beneficial effect of higher ribavirin concentrations in
HCV infected patients treated with pegylated interferon and ribavirin. For countries where
peg-interferon and ribavirin dual therapy is still first-line treatment our results may be of direct
value to improve outcomes.
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